Administration, Intravesical
"Administration, Intravesical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
Descriptor ID |
D000283
|
MeSH Number(s) |
E02.319.267.120.505
|
Concept/Terms |
Administration, Intravesical- Administration, Intravesical
- Intravesical Drug Administration
- Drug Administration, Bladder
- Administration, Intravesical Drug
- Administrations, Intravesical Drug
- Drug Administration, Intravesical
- Drug Administrations, Intravesical
- Intravesical Drug Administrations
- Intravesical Administration
- Administrations, Intravesical
- Intravesical Administrations
- Bladder Drug Administration
- Administration, Bladder Drug
- Administrations, Bladder Drug
- Bladder Drug Administrations
- Drug Administrations, Bladder
Instillation, Bladder- Instillation, Bladder
- Bladder Instillation
- Bladder Instillations
- Instillations, Bladder
- Intravesical Instillation
- Instillation, Intravesical
- Instillations, Intravesical
- Intravesical Instillations
Intravesical Injection- Intravesical Injection
- Injections, Intravesical
- Injection, Intravesical
- Intravesical Injections
|
Below are MeSH descriptors whose meaning is more general than "Administration, Intravesical".
Below are MeSH descriptors whose meaning is more specific than "Administration, Intravesical".
This graph shows the total number of publications written about "Administration, Intravesical" by people in this website by year, and whether "Administration, Intravesical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 2 | 2 |
1999 | 0 | 1 | 1 |
2000 | 0 | 2 | 2 |
2001 | 0 | 2 | 2 |
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 2 | 2 |
2006 | 0 | 3 | 3 |
2007 | 0 | 3 | 3 |
2008 | 0 | 5 | 5 |
2009 | 0 | 3 | 3 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 5 | 5 |
2013 | 0 | 7 | 7 |
2014 | 0 | 1 | 1 |
2015 | 0 | 7 | 7 |
2016 | 0 | 8 | 8 |
2017 | 0 | 5 | 5 |
2018 | 0 | 9 | 9 |
2019 | 0 | 2 | 2 |
2020 | 0 | 8 | 8 |
2021 | 0 | 9 | 9 |
2022 | 0 | 6 | 6 |
2023 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Intravesical" by people in Profiles.
-
Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
-
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Gu?rin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 10; 6(5):531-534.
-
Bacillus Calmette-Gu?rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal? BJU Int. 2023 10; 132(4):384-386.
-
The current status of gene therapy in bladder cancer. Expert Rev Anticancer Ther. 2023 05; 23(5):531-543.
-
Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. Urol Oncol. 2023 05; 41(5):211-218.
-
NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.
-
All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Gu?rin Response in High-Grade Ta Tumors. J Urol. 2022 08; 208(2):284-291.
-
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 10; 5(5):505-516.